Sperzel W D, Glassman H N, Jordan D C, Luther R R
Am J Med. 1986 May 23;80(5B):77-81. doi: 10.1016/0002-9343(86)90857-0.
The safety of terazosin, an effective agent for the treatment of hypertension, was assessed by analyzing data from 1,006 hypertensive patients who were enrolled in short-term and/or long-term studies. The total experience with terazosin in this article represents 422.5 patient-years. Changes in pulse rate measurements from pretreatment to posttreatment were not significantly different between the terazosin- and placebo-treated patients (-1.0 beat per minute for the terazosin group and -1.0 beat per minute for the placebo group, in the supine position). Dizziness, headache, and asthenia were the most commonly reported adverse experiences among all terazosin-treated patients, although the incidence of headache in placebo-controlled trials was not significantly different between the terazosin and placebo groups. As a whole, patients receiving terazosin had a tendency to gain small amounts of weight (2 pounds). In addition, there was a trend for slight decreases in hemoglobin, hematocrit, white blood cell count, total protein, and albumin levels in those patients who received terazosin, suggesting hemodilution. Overall, terazosin was shown to be safe in patients with mild to moderate essential hypertension.
通过分析1006例纳入短期和/或长期研究的高血压患者的数据，评估了治疗高血压的有效药物特拉唑嗪的安全性。本文中特拉唑嗪的总体研究经历相当于422.5患者年。特拉唑嗪治疗组和安慰剂治疗组患者从治疗前到治疗后的脉搏率测量变化无显著差异（仰卧位时，特拉唑嗪组每分钟下降1.0次，安慰剂组每分钟下降1.0次）。头晕、头痛和乏力是所有接受特拉唑嗪治疗患者中最常报告的不良经历，尽管在安慰剂对照试验中，特拉唑嗪组和安慰剂组的头痛发生率无显著差异。总体而言，接受特拉唑嗪治疗的患者有轻微体重增加的趋势（2磅）。此外，接受特拉唑嗪治疗的患者血红蛋白、血细胞比容、白细胞计数、总蛋白和白蛋白水平有轻微下降的趋势，提示血液稀释。总体而言，特拉唑嗪对轻至中度原发性高血压患者显示出安全性。
